Plasma Exchange with Albumin Replacement for Alzheimer's Disease Treatment
Author Information
Author(s): R. Gonzalo, Minguet Carla, Ortiz Ana María, Bravo María Isabel, López Oscar L., Boada Mercè, Ruiz Agustín, Costa Montserrat
Primary Institution: Grifols Scientific Innovation Office
Hypothesis
Can plasma exchange with albumin replacement impact the inflammatory status of Alzheimer's disease patients and alter the relationship between inflammatory mediators and cognitive measures?
Conclusion
Plasma exchange with albumin replacement significantly reduced inflammatory mediators in Alzheimer's disease patients and was associated with improved clinical outcomes.
Supporting Evidence
- PE‐Alb significantly reduced levels of inflammatory mediators in both serum and cerebrospinal fluid.
- Increased serum MIP‐1α levels were associated with worsening cognitive scores in the placebo group.
- Changes in inflammatory mediators were linked to clinical outcomes in Alzheimer's disease patients.
Takeaway
This study shows that a treatment called plasma exchange can help reduce inflammation in the brains of Alzheimer's patients, which might help them feel better.
Methodology
Serum and cerebrospinal fluid samples from 142 Alzheimer's disease patients were analyzed for changes in 19 inflammatory mediators before and after treatment.
Potential Biases
Potential bias due to the limited number of inflammatory mediators evaluated and the sample collection timeframe.
Limitations
The study was limited by the sample size and the number of inflammatory biomarkers measured.
Participant Demographics
Patients diagnosed with mild-to-moderate Alzheimer's disease, aged 18 to 26 on the Mini-Mental State Examination.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website